What is Celyad?
Founded in 2007 and headquartered in Mont-Saint-Guibert, Belgium, Celyad operates at the intersection of advanced biotechnology and oncology. The company is primarily recognized for its innovative CAR-T cell-based therapy platform, which utilizes sophisticated cell engineering techniques to target both solid and hematologic tumors. By developing both autologous and allogeneic therapeutic candidates, Celyad aims to address significant unmet medical needs in conditions such as acute myeloid leukemia and metastatic colorectal cancer. As a publicly traded entity on Euronext and the Nasdaq, the company maintains a rigorous focus on translating scientific discovery into clinical outcomes, positioning itself as a key player in the global immunotherapy landscape.
How much funding has Celyad raised?
Celyad has raised a total of $180.7M across 4 funding rounds:
Series B
$8.1M
Stock Offering
$100.1M
Share Placement
$40M
Share Placement
$32.5M
Series B (2009): $8.1M with participation from Grifols, Hunza Ventures SCA Hunza Ventures, and Life Sciences Research Partners
Stock Issuance/Offering (2015): $100.1M, investors not publicly disclosed
Share Placement (2021): $40M supported by Lincoln Park Capital
Share Placement (2021): $32.5M featuring Fortress Investment Group
Key Investors in Celyad
Grifols
Grifols is a global healthcare leader based in Spain, specializing in plasma-derived medicines and diagnostic solutions with a long-term commitment to medical innovation.
Hunza Ventures
Hunza Ventures is a venture capital firm focused on life sciences and information technology, providing strategic partnership and sector expertise to early-stage innovators.
Life Sciences Research Partners
Life Sciences Research Partners is a non-profit scientific institution dedicated to supporting biomedical and biotechnological research projects with a focus on long-term health outcomes.
What's next for Celyad?
Following the recent major strategic investment, Celyad is well-positioned to accelerate its clinical development roadmap. The infusion of capital is expected to bolster the company's ability to navigate the high-cost environment of late-stage clinical trials and regulatory approval processes. Strategic priorities likely include the optimization of its allogeneic CAR-T platform, which offers the potential for off-the-shelf treatment solutions, thereby enhancing scalability compared to traditional autologous methods. As the firm continues to refine its therapeutic candidates, the focus will remain on achieving key data milestones that validate the efficacy and safety of its pipeline, ultimately aiming to secure a competitive advantage in the rapidly evolving oncology market.
See full Celyad company page
